Novo Nordisk and Anthropic Partner for AI Drug Discovery
The collaboration integrates the Claude AI model to accelerate R&D for chronic disease treatments.
A high-tech laboratory environment showing digital screens with molecular structures and neural network patterns, representing the use of AI in pharmaceutical research.
Photo: Kronos News
Novo Nordisk, now operating as Novo, announced a strategic collaboration with AI lab Anthropic on September 18, 2026 [1][2]. The Danish pharmaceutical leader will integrate the Claude AI model into its research and development workflows [1]. This partnership aims to leverage advanced biological reasoning to compress drug discovery timelines [1][3].
By utilizing Anthropic's technology, Novo intends to develop new treatments for various chronic diseases [1][2]. The deal focuses on enhancing scientific research capabilities through sophisticated data analysis [2][3]. Industry experts suggest the integration will allow for more efficient identification of potential drug candidates [2].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
qz.com
https://qz.com/novo-nordisk-anthropic-claude-drug-discovery-091626
- 2.↗
biopharmadive.com
https://www.biopharmadive.com/news/novo-anthropic-ai-drug-discovery-development-deal/830540/
- 3.↗
healthcare-digital.com
https://healthcare-digital.com/news/novo-anthropic-partnering-on-claude-ai-drug-discovery
Related stories
View all
About the author
Kronos News Desk covers news and editorial analysis for Kronos News.